Eli Lilly settles with Minnesota to cap insulin at $35 a month for uninsured residents
Minnesota Attorney General Keith Ellison announced a settlement with Eli Lilly under which Lilly agreed to cap insulin prices at $35 per month for uninsured Minnesotans and donate insulin to free clinics serving low-income patients. No liability was admitted. The settlement built on Minnesota's 2020 Alec Smith Insulin Affordability Act.
Minnesota Attorney General Keith Ellison announced on February 7, 2024 that Eli Lilly and Company had agreed to settle a state investigation into its insulin pricing practices. Under the settlement, Lilly committed to cap out-of-pocket insulin costs at $35 per month for uninsured Minnesota residents, to cap costs for underinsured residents at $35 per month for up to 12 months, and to donate insulin to free clinics serving low-income patients at up to 15 clinic sites in the state. Lilly did not admit liability.
Minnesota passed the Alec Smith Insulin Affordability Act in 2020, named for a 26-year-old diabetic who rationed his insulin and died in 2017 after losing his parents' insurance coverage. The law created an emergency programme allowing pharmacies to dispense a 30-day supply of insulin for $35 to patients who cannot afford it, with manufacturers reimbursing the cost. Attorney General Ellison's office subsequently opened investigations into manufacturers' pricing practices, leading to the 2024 settlement with Lilly.
The agreement was structured similarly to settlements that other states and the federal government reached with insulin manufacturers in the period. In March 2023 Eli Lilly announced voluntarily that it would cap out-of-pocket costs for insulin at $35 per month for commercially insured US patients and expand its insulin value programme, moves the company made before any settled state enforcement action. The Minnesota settlement gave those commitments legal force for uninsured state residents and added the clinic donation obligation.
Lilly is also named as a defendant in the insulin pricing lawsuit filed by the Texas Attorney General in October 2024, which names multiple manufacturers and PBMs and alleges coordinated conduct to keep insulin prices high. Texas AG Ken Paxton filed a separate action against Lilly in August 2025 alleging that nurse and reimbursement support services operated as kickbacks. The FTC's July 2024 interim PBM report cited insulin as its primary example of how rebate-driven formulary practices disadvantaged lower list price products, implicating both manufacturers and PBMs in the broader pricing structure.
Lilly's Humalog, Basaglar and Humulin brands are among the most widely prescribed insulin products in the US. Lilly said the settlement confirmed the company's commitment to making insulin affordable. No monetary penalty was assessed against Lilly under the agreement.
Cite this report
The Precedent. "Eli Lilly settles with Minnesota to cap insulin at $35 a month for uninsured residents." August 26, 2026. https://theprecedent.org/article/eli-lilly-settles-with-minnesota-to-cap-insulin-at-35-a-month-for-uninsured-resi
